Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.

Before fixing the cut-off, we examined alternative thresholds (20%, 25%, 30%, 50%) in sensitivity analyses: at 20% the OS difference within the high Ki-67 stratum was non-significant ( P = 0.19), approached significance at 25% ( P = 0.09), became significant at 30% ( P = 0.001), and was more pronounced at 50% ( P < 0.001), at the cost of excluding patients with Ki-67 between 30 and 50% who may still benefit from ICI-chemo.

also in 8,237 other papers